← back to search

Jeffrey S. Wagener

University of Colorado Denver · US
Area of research
Pulmonary and Respiratory Medicine · Sociology and Political Science
Research interest
Research focused on Cystic fibrosis and Exacerbation, with related work in Lung function, Ivacaftor, Antibiotics. Notable publications include 'Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data', 'Risk factors for rate of decline in FEV1 in adults with cystic fibrosis', and 'Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis'.
h-index
citations
717
works
10
NIH funding
primary concept
email

Recent publications

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis
Pediatric Pulmonology 2019cited by 27position: firstdoi
Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis
Annals of the American Thoracic Society 2017cited by 42position: middledoi
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation
Journal of Cystic Fibrosis 2017cited by 18position: firstdoi
Strengthening care teams to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative
Patient Preference and Adherence 2017cited by 13position: lastdoi
Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data
American Journal of Respiratory and Critical Care Medicine 2015cited by 238position: middledoi
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function
The Journal of Pediatrics 2015cited by 60position: middledoi
Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function
The Journal of Pediatrics 2013cited by 41position: middledoi
Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
Journal of Cystic Fibrosis 2012cited by 113position: middledoi
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
Pediatric Pulmonology 2012cited by 112position: firstdoi
Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms
Pediatric Pulmonology 2012cited by 53position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 8 papers (2012–2019)Michael W. Konstan · The Ohio State University Wexner Medical Center8 papers (2012–2019)Wayne J. Morgan · University of Illinois Chicago7 papers (2012–2019) · 5 papers (2013–2019)Donald R. VanDevanter · Case Western Reserve University4 papers (2012–2019)Ashley Yegin · AbbVie (United States)2 papers (2012–2013) · 2 papers (2012–2012)Warren E. Regelmann · University of Minnesota, Twin Cities2 papers (2012–2012)Gregory S. Sawicki · Boston Children's Hospital2 papers (2015–2017) · 2 papers (2015–2017)Alice Gray · University of Colorado Denver1 papers (2017–2017)Staci Thrasher Self · University of Alabama at Birmingham1 papers (2017–2017)Michael S. Schechter · Virginia Commonwealth University1 papers (2012–2012)Richard B. Moss · Palo Alto University1 papers (2017–2017)Charles A. Johnson · Medical University of South Carolina1 papers (2015–2015)Christopher H. Goss · University of Kentucky1 papers (2017–2017)Nicole Mayer-Hamblett · Case Western Reserve University1 papers (2017–2017)Eric P. Elkin · Indiana University1 papers (2012–2012) · 1 papers (2017–2017)